COLLABORATIVE DRUG DISCOVERY, INC.

COLLABORATIVE DRUG DISCOVERY, INC. specializes in developing and delivering secure, cloud-based computational platforms for biomedical research and drug discovery. Their core capabilities center on high-performance computing infrastructure, secure data hosting, and custom software systems tailored for complex biological datasets. They design and maintain encrypted data vaults and subscription-based access systems that enable secure collaboration among researchers, with a focus on neurotherapeutics and precision medicine applications. Technical expertise includes secure web hosting, data processing pipelines, user-access control frameworks, and custom programming for scientific workflows, ensuring compliance with federal data integrity and confidentiality standards. The company has established a consistent track record supporting the Department of Defense and the Department of Health and Human Services. For the DoD, they provide secure computational infrastructure for sensitive drug discovery initiatives, while for HHS, they deliver centralized IT systems that integrate multi-institutional research data for the NIH Blueprint Neurotherapeutics Network. Their engagements reflect a pattern of delivering mission-critical, data-intensive platforms to agencies requiring rigorous security and interoperability in life sciences research. Their primary industry focus lies in computing infrastructure services and custom computer programming, specifically serving the biomedical and federal research sectors. They position themselves as a niche provider of secure, scalable platforms that bridge computational biology with enterprise-grade IT systems, enabling large-scale collaboration among government-funded scientific teams. As a small business structured as a 2L entity based in Burlingame, California, COLLABORATIVE DRUG DISCOVERY, INC. operates without federal certifications but maintains a focused presence in the federal life sciences technology market, delivering specialized solutions to agencies engaged in advanced therapeutic development.